Rho(D) immune globulin: A double blind clinical trial

Stenchever, Morton A.; Davies, I. John; Weisman, R. Bruce; Gross, Samuel

doi:10.1016/0002-9378(70)90286-3

Cited by 3 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… A Western Canadian Trial : Primary study: Chown 1969; Other publications not used: Buchanan 1969 [ 45 ], Godel 1968 [ 46 ] B Combined Study (England and Baltimore) : Primary study: No author listed 1971 [ 34 ]; Other publications not used: Clarke 1965 [ 47 ], Clarke 1968 [ 48 ], Finn 1968 [ 49 ], Woodrow 1965 [ 50 ], No author listed 1966 [ 51 ] C International trial : Primary study: White 1970 [ 38 ]; Subgroup data for dosage taken from Ascari 1968 [ 31 ]; Other publications not used: Ascari 1969 [ 52 ], Bishop 1968 [ 53 ], Bishop 1969 [ 54 ], Bryant 1969 [ 55 ], Freda 1966 [ 56 ], Freda 1967 [ 57 ], Jennings 1968 [ 58 ], Pollack 1968 [ 59 ], Robertson 1968 [ 60 ], Robertson 1969 [ 61 ], Stenchever 1970 [ 62 ], Symposium 1971 [ 63 ] D Part of the Combined study, but reports only on those with <0.2 ml of Rh-positive fetal blood in their circulation. All other Combined study publications do not include these women.…”

Section: Resultsmentioning

confidence: 99%

“… C International trial : Primary study: White 1970 [ 38 ]; Subgroup data for dosage taken from Ascari 1968 [ 31 ]; Other publications not used: Ascari 1969 [ 52 ], Bishop 1968 [ 53 ], Bishop 1969 [ 54 ], Bryant 1969 [ 55 ], Freda 1966 [ 56 ], Freda 1967 [ 57 ], Jennings 1968 [ 58 ], Pollack 1968 [ 59 ], Robertson 1968 [ 60 ], Robertson 1969 [ 61 ], Stenchever 1970 [ 62 ], Symposium 1971 [ 63 ] …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Antenatal and postpartum prevention of Rh alloimmunization: A systematic review and GRADE analysis

et al. 2020

View full text Add to dashboard Cite

Background Existing systematic reviews of Rh immunoprophylaxis include only data from randomized controlled trials, have dated searches, and some do not report on all domains of risk of bias or evaluate the certainty of the evidence. Our objective was to perform an updated review, by including new trials, any comparative observational studies, and assessing the certainty of the evidence using the GRADE framework. Methods We searched MEDLINE, Embase and the Cochrane Library from 2000 to November 26, 2019. Relevant websites and bibliographies of systematic reviews and guidelines were searched for studies published before 2000. Outcomes of interest were sensitization and adverse events. Risk of bias was evaluated with the Cochrane tool and ROBINS-I. The certainty of the evidence was performed using the GRADE framework. Results Thirteen randomized trials and eight comparative cohort studies were identified, evaluating 12 comparisons. Although there is some evidence of beneficial treatment effects (e.g., at 6months postpartum, fewer women who received RhIg at delivery compared to no RhIg became sensitized [70 fewer sensitized women per 1,000 (95%CI: 67 to 71 fewer); I 2 = 73%]), due to very low certainty of the evidence, the magnitude of the treatment effect may be overestimated. The certainty of the evidence was very low for most outcomes often due to high risk of bias (e.g., randomization method, allocation concealment, selective reporting) and imprecision (i.e., few events and small sample sizes). There is limited evidence on prophylaxis for invasive fetal procedures (e.g. amniocentesis) in the comparative literature, and few studies reported adverse events.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Antenatal and postpartum prevention of Rh alloimmunization: A systematic review and GRADE analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

Anti-D administration after childbirth for preventing Rhesus alloimmunisation

Crowther

Middleton

1997

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Clinical value of different anti-D immunoglobulin strategies for preventing Rh hemolytic disease of the fetus and newborn: A network meta-analysis

Xie

Bao

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Background Several anti-D immunoglobulin strategies exist for preventing Rh hemolytic disease of the fetus and newborn. This study systematically assessed the clinical value of those therapeutic strategies. Methods The Web of Science, PubMed, EMBASE, China National Knowledge Infrastructure (CNKI) and Wanfang databases were searched for eligible studies that evaluated the value of different anti-D immunoglobulin strategies in preventing maternal anti-D antibody sensitization. Combined odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated. The network meta-analysis was conducted using Stata 14.2 and WinBUGS 1.4.3 software. Results Twenty-four original studies involving 64860 patients were included. Among all therapeutic measures, injecting 300 μg anti-D immunoglobulin at 28 and 34 gestational weeks (antenatal 5/E) appeared to be the most effective measure for preventing maternal antibody sensitization (surface under the cumulative ranking curve [SUCRA] = 96.8%), while a single injection at 28 gestational weeks (SUCRA = 89.2%) was the second most effective. Administering no injection or a placebo (SUCRA = 0.0%) was the least effective intervention measure. Conclusion Among the therapeutic measures, antenatal 5/E appeared to be the best method for reducing the positive incidence of anti-D antibodies in the maternal serum; thus, it may be the most effective treatment for preventing fetal hemolytic disease.

show abstract

Rho(D) immune globulin: A double blind clinical trial

Cited by 3 publications

References 3 publications

Antenatal and postpartum prevention of Rh alloimmunization: A systematic review and GRADE analysis

Antenatal and postpartum prevention of Rh alloimmunization: A systematic review and GRADE analysis

Anti-D administration after childbirth for preventing Rhesus alloimmunisation

Clinical value of different anti-D immunoglobulin strategies for preventing Rh hemolytic disease of the fetus and newborn: A network meta-analysis

Contact Info

Product

Resources

About